Announcements Trials
Browse Landscape

Phase

Phase 1 11Phase 2 6Phase 3 1Phase 1/2 1

Status

Recruiting 3Completed 3

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 2Sarcoma 2Thoracic 1Endocrine 1Breast 1

Conditions

Endometrial Neoplasms 7Ovarian Neoplasms 6Neoplasms 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Neuroendocrine 2Vulvar Neoplasms 1Vaginal Neoplasms 1Turcot syndrome 1Small Cell Lung Carcinoma 1Sarcoma, Clear Cell 1Sarcoma 1Recurrence 1Penile Neoplasms 1Pathologic Complete Response 1Neoplasms, Second Primary 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1MMRd/MSI-H Stage II-III Endometrial Cancer 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × dostarlimab × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06333314 2025-12-02

Pan-MSI-ACSE

UNICANCER

Phase 2 Recruiting
120 enrolled
EndocrineSarcoma

Neoplasm Metastasis, Neoplasms, Sarcoma, Adrenocortical Carcinoma, Carcinoma, Neuroendocrine

NCT06926673 2025-07-03

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

GlaxoSmithKline

Phase 2 Completed
62 enrolled 36 charts
Tumor-Agnostic

Neoplasms

NCT03739710 2025-06-15

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

GlaxoSmithKline

Phase 2 Completed
175 enrolled 5 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT05855811 2024-07-15

PREDOSTAR

Centre Leon Berard

Phase 2 Recruiting
400 enrolled

Neoplasms, Recurrence, Neoplasms, Second Primary

NCT03308942 2023-10-16

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

Tesaro, Inc.

Phase 2 Completed
53 enrolled 35 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡